HPS Pharmacies wishes to advise that there is a supply interruption for octreotide ampoules as follows:
| Product | ARTG | Anticipated availability |
| Octreotide GH 50 micrograms/1 mL | 148404 | Early March 2025* |
| Octreotide GH 100 micrograms/1 mL | 148402 | End May 2024 |
| Octreotide GH 500 micrograms/1 mL | 14803 | End December 2024 |
| Sandostatin® 50 microgram/1mL | 42192 | Presently* |
| Sandostatin® 100 microgram/1mL | 42193 | Mid-June 2024 |
*Limited Octreotide GH 50 mcg/1 mL stock is currently available in some states. However, a long-term supply interruption is expected to affect all states from late May 2024 until early March 2025. Warehouse supplies of Sandostatin® 50 mcg/1mL are currently being replenished and are expected to be available shortly.
An internationally registered alternative of each strength is awaiting final approval from the TGA for supply under Section 19A of the Therapeutic Goods Act 1989. The S19A alternative brand is Octreotide Acetate Omega (Canada), and stock is expected to be released by mid to late May 2024. This product is supplied as vials which are labelled for subcutaneous and intravenous use. The Australian product information should be referred to for dosing and administration recommendations.
Octreotide modified-release injection (Sandostatin® LAR) is not affected by this notice.
Retain this notice in a prominent position, including in other related business units until supplies return to normal. Report any problems identified with medicines, vaccines or medical devices to the TGA.
Should you require further information regarding this matter, please contact your pharmacist at HPS Pharmacies.
Subscribe Knowledge Centre Updates
Enter your details to receive Knowledge Centre updates